SLIT3-AS2: A Potential Drug Target and Biomarker (G101927969)

Target Name: SLIT3-AS2

NCBI ID: G101927969

SLIT3-AS2

Other Name(s): SLIT3 antisense RNA 2

SLIT3-AS2: A Potential Drug Target and Biomarker

SLIT3-AS2, also known as SLIT3 antisense RNA 2, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SLIT3-AS2 is derived from the SLIT3 gene, which is located on chromosome 12q22. SLIT3-AS2 is expressed in human tissues and has been shown to play a role in various biological processes, including cell signaling, DNA replication, and metabolism.

The discovery of SLIT3-AS2 as a potential drug target and biomarker comes from a study by the research team led by Dr. Xujiong Ye at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified SLIT3-AS2 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The team's findings suggest that SLIT3-AS2 can inhibit the activity of the protein kinase A??, which is involved in the development and progression of Alzheimer's disease. The researchers found that SLIT3-AS2 can also interact with the protein heat shock protein HSP70, which may contribute to its potential as a drug target.

In addition to its potential as a drug target, SLIT3-AS2 has also been identified as a potential biomarker for various diseases. The team's study also showed that SLIT3-AS2 levels were elevated in the brains of individuals with Alzheimer's disease, which may indicate its potential as a diagnostic biomarker.

The team's findings have important implications for the development of new treatments for various diseases. By inhibiting the activity of SLIT3-AS2, researchers may be able to extend the lifespan of people with Alzheimer's disease, or even reverse the disease's effects.

SLIT3-AS2 may also have potential as a target for other diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The team's findings suggest that SLIT3-AS2 can inhibit the activity of the protein kinase A??, which is involved in the development and progression of Alzheimer's disease.

The researchers found that SLIT3-AS2 can also interact with the protein heat shock protein HSP70, which may contribute to its potential as a drug target. HSP70 is a protein that helps protect cells from the effects of heat stress, and its levels may be elevated in diseases where cells are under stress, such as cancer.

In conclusion, SLIT3-AS2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The team's findings suggest that SLIT3-AS2 can inhibit the activity of the protein kinase A?? and interact with the protein heat shock protein HSP70, which may make it a valuable target for the development of new treatments for various diseases. Further research is needed to confirm these findings and determine the full potential of SLIT3-AS2 as a drug and biomarker.

Protein Name: SLIT3 Antisense RNA 2

The "SLIT3-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLIT3-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets